You want a low-risk,
high-return investment – and do good with it!
Cancer metastasis is in urgent need of better treatments. MetaMol’s antibody drug candidate has huge potential. With the right partnerships, we will bring it to clinical trials.
Large market size
Need for metastasis treatments
First-in-class drug
Low risk
antibody development
A Cancer Progression Platform
Breast Cancer as the First Clinical Indication
MetaMol is building a next-generation oncology platform focused on tumor-specific splice variants that drive metastatic disease.
Breast cancer is our lead indication, but the underlying platform technology is designed to scale across multiple solid tumors where metastatic spread determines mortality.
Market Opportunity
MetaMol is positioned to capture significant value in two high-impact markets: Diagnostics: Serving 1.6 million patients in the U.S., our test addresses a $70B burden with a serviceable addressable market (SAM) of $800M. Therapeutics: Targeting 43,000 advanced breast cancer patients, our antibody therapy addresses a $3B treatment cost burden. The broader monoclonal antibody market is projected to reach $300B globally by 2027.